stock graphs


China appears to be sending a message to President-elect Donald Trump: Good luck competing against us on manufacturing.

Mere hours after Trump, Vice President-elect Mike Pence and Carrier announced a deal to keep nearly 1,000 factory jobs in the U.S., a top Chinese newspaper published an analysis piece with the headline: “China would benefit from Trump’s effort to bring manufacturing jobs back to U.S.”

The commentary ran in the “business opinion” section of the Global Times, a newspaper backed by the Communist Party.


“It will be almost impossible for the [U.S.] to restore its glory as a major manufacturing powerhouse under his presidency,” the piece says. The author is a reporter for the Global Times.

If companies like Apple (AAPL, Tech30) move factory jobs back to the U.S. in a “show of patriotism,” it will raise costs dramatically, the reporter argues. That opens the door for Chinese companies like smartphone makers Huawei and Xiaomi to undercut Apple on the world market.

stock graphs: Container Store (The)(TCS)


Advisors’ Opinion:

  • [By Monica Gerson]

    Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.

    J & J Snack Foods Corp (NASDAQ: JJSF) is estimated to post its quarterly earnings at $0.78 per share on revenue of $231.58 million.

stock graphs: Jazz Pharmaceuticals Inc.(JAZZ)

Advisors’ Opinion:

  • [By Jim Robertson]

    The earnings report summarized the following recent milestones:


    The formation of a Scientific Advisory Board (SAB) to provide expert guidance and insight as the Company advances towards product commercialization. in October, Pfenex announced the hiring of Steven Sandoval as Chief Manufacturing Officer.Steven has over 25 years of commercial biopharmaceutical engineering and operations experience, specializing in commercial operations, facility design and licensure of large scale biopharmaceutical commercial manufacturing facilities. Following the announcement in August of the positive Phase 1 trial data for Pfenex’s recombinant anthrax vaccine, discussions with BARDA have been progressing. Pfenex anticipates initiating the PF708 pivotal clinical program by year end. Pfenex entered into a collaboration with Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on multiple hematology/oncology product candidates in July. Regulatory feedback for PF529, Pfenex’s biosimilar candidate to Neulasta (pegfilgrastim), is expected by the end of 2016 and following that feedback, the development path and potential timeline will be outlined.


    Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.

stock graphs: Allied Motion Technologies, Inc.(AMOT)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggestedsmall cap precision and specialty motion control stock Allied Motion Technologies (NASDAQ: AMOT) as a possible long position:

stock graphs: PACCAR Inc.(PCAR)


Advisors’ Opinion:

  • [By Jim Cramer]

    Despite the weak revenue results, PCAR has outperformed against the industry average of 21.6%. Since the same quarter one year prior, revenues slightly dropped by 1.6%. The declining revenue has not hurt the company’s bottom line, with increasing earnings per share.

     

  • [By Jim Cramer]

    PACCAR INC has improved earnings per share by 16.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, PACCAR INC increased its bottom line by earning $3.82 versus $3.30 in the prior year. This year, the market expects an improvement in earnings ($4.58 versus $3.82).


     

  • [By JPMorgan]

    We are Neutral on PCAR as the company faces the risk of both lower volume and margin pressure from declining demand in its core NA HD truck business in 2016. However, we believe PCAR should command a premium valuation due to its track record of solid execution. In addition, PCAR pays out a normal and a special dividend which, in total, should equal ~50% of net income and currently offers a yield of 4.1% (JPMe total payout of ~$2.12/share) making it potentially attractive to income-oriented investors. 

  • [By Jim Cramer]

    The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Machinery industry and the overall market, PACCAR INC’s return on equity exceeds that of both the industry average and the S&P 500.

     

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Machinery industry. The net income increased by 16.1% when compared to the same quarter one year prior, going from $371.40 million to $431.20 million.

     

Leave a Reply

Your email address will not be published. Required fields are marked *